Chronic inflammation, once considered simply a response to injury or infection, is now recognized as a central player in the development and progression of cancer. From subtle, ongoing immune activation to full-blown inflammatory responses, this complex biological process can both fuel tumor growth and, paradoxically, offer new avenues for therapeutic intervention. Researchers are increasingly focused on understanding the intricate interplay between inflammation and the immune system, particularly as it relates to the effectiveness of modern cancer treatments like immunotherapy. A recent review published in the Journal of Exploratory Research in Pharmacology synthesizes decades of research, highlighting key signaling pathways, immune cell interactions, and emerging technologies poised to reshape cancer care.
The link between inflammation and cancer isn’t new. As early as the 19th century, Rudolf Virchow observed inflammatory cells in tumor tissues, suggesting a connection. Today, it’s understood that up to 20% of all cancers are linked to chronic infections, autoimmune diseases, or environmental factors that trigger persistent inflammation. This chronic state creates a tumor-permissive microenvironment, allowing cancer cells to thrive, evade immune detection, and spread. Understanding this dynamic is crucial for developing more effective cancer therapies.
The Inflammatory Landscape Within Tumors
At the heart of inflammation’s role in cancer are several key signaling pathways. NF-κB and STAT3, for example, are consistently activated in cancer cells, promoting their survival, growth, and ability to form new blood vessels – a process called angiogenesis. These pathways also suppress the immune system, shielding the tumor from attack. Another important player is the COX-2/PGE2 pathway, which drives proliferation and recruits myeloid-derived suppressor cells (MDSCs) to the tumor site. These MDSCs, along with other immune cells like M2-polarized tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and N2 neutrophils, actively suppress anti-tumor immunity, creating an environment where cancer can flourish.
The complexity of this inflammatory landscape is further revealed through single-cell analyses, which demonstrate the remarkable heterogeneity of immune cells within the tumor microenvironment. These analyses are helping researchers identify specific targets for therapeutic intervention, aiming to reprogram these cells to fight cancer rather than support it.
Immunotherapy and the Inflammation Connection
Immunotherapy, particularly immune checkpoint inhibitors (ICIs) like anti-PD-1, anti-PD-L1, and anti-CTLA-4, has revolutionized cancer treatment, but its effectiveness varies significantly between patients. Elevated levels of the cytokine IL-6, a key inflammatory molecule, have been identified as a predictor of resistance to these therapies. The recent approval of LAG-3 blockade (relatlimab) in 2024 represents another step forward, but understanding how inflammation influences response remains a critical area of research.
Other immunotherapeutic approaches, such as CAR-T cell therapy, also face challenges in solid tumors due to the suppressive nature of the tumor microenvironment. Researchers are exploring ways to overcome this resistance, including using CRISPR gene editing to enhance the persistence of CAR-T cells in inflammatory conditions. Personalized neoantigen vaccines and oncolytic viruses are also under investigation, often in combination with anti-inflammatory agents, to boost their effectiveness.
Translational Strategies and Emerging Therapies
Beyond immunotherapy, researchers are exploring a range of translational strategies to target inflammation in cancer. Drug repurposing – finding new uses for existing drugs – is one promising avenue. Aspirin, for example, has been shown to reduce the risk of colorectal cancer and metastasis, although COX-2 inhibitors are used in the treatment of familial adenomatous polyposis (FAP). Statins, commonly used to lower cholesterol, are also being investigated for their potential anti-cancer effects.
Directly targeting cytokines, such as IL-6 and TNF, is another approach. Clinical trials are underway evaluating the use of tocilizumab (anti-IL-6R), siltuximab (anti-IL-6), and infliximab (anti-TNF) in various cancers. Studies planned for 2025 will combine IL-6 blockade with ICIs in patients with pancreatic cancer. Researchers are working to develop inhibitors of NF-κB and STAT3, aiming to disrupt the signaling pathways that drive inflammation and tumor growth. Preclinical models, including humanized mice and multi-omics studies, are crucial for testing these strategies and identifying new targets.
The Future of Inflammation-Targeted Cancer Therapy
Looking ahead, several emerging technologies hold immense promise for refining cancer treatment. The gut microbiome, for instance, is increasingly recognized as a key regulator of inflammation and immune response. Studies have shown that certain bacteria, such as Bifidobacterium and Akkermansia, correlate with improved responses to immunotherapy, leading to investigations into fecal microbiota transplantation (FMT) and CRISPR-based microbiome editing.
Artificial intelligence (AI) and machine learning are also playing a growing role, with models being developed to predict prognosis, identify patients who are most likely to respond to CAR-T therapy, and integrate imaging and text data for more accurate diagnosis and treatment planning. Gene editing technologies, like CRISPR-Cas9, offer the potential to directly modify immune cells and tumor cells, enhancing their anti-cancer activity. Single-cell and spatial omics technologies are providing unprecedented insights into the complex interactions within the tumor microenvironment, while nanotechnology and liquid biopsies are enabling more precise monitoring of treatment response.
The integration of these technologies, combined with a deeper understanding of the interplay between inflammation and cancer, offers a path towards truly personalized cancer care. Researchers are exploring ADC-delivered anti-inflammatory payloads and rational combination therapies targeting multiple pathways simultaneously, like NF-κB and STAT3. Pharmacogenomics, the study of how genes affect a person’s response to drugs, may also play a role in tailoring anti-inflammatory treatments to individual patients.
tackling chronic inflammation represents a significant opportunity to improve cancer prevention, treatment, and outcomes. As research continues to unravel the complexities of this process, the prospect of harnessing the power of the immune system to fight cancer becomes increasingly attainable.
The study, recently published in the Journal of Exploratory Research in Pharmacology, underscores the need for continued investigation into these promising avenues.
Source:
Journal reference:
Yang, W. (2025). Cancer and Inflammation: Immunologic Interplay, Translational Advances, and Clinical Strategies. Journal of Exploratory Research in Pharmacology. DOI: 10.14218/jerp.2025.00045. https://www.xiahepublishing.com/2572-5505/JERP-2025-00045
